Company Monitoring Page for Circassia

latest headlines for company on cafepharma

A bruised Circassia offloads debt by returning COPD drugs to AstraZeneca
Endpoints
Thu, 04/9/20 - 10:37 am
Tags:
Circassia, AstraZeneca, COPD
COPD space about to have another drug
Bizjournals
Thu, 04/18/19 - 09:47 am
Tags:
Circassia, COPD, Duaklir Pressair, FDA
Circassia gets dual boost for US COPD drugs
Pharmaforum
Mon, 04/1/19 - 10:39 am
Tags:
Circassia, FDA, COPD, Tudorza, Duaklir, AstraZeneca
Four years after mega IPO, Circassia set for small-cap exchange
Fierce Biotech
Tue, 12/11/18 - 10:24 am
Tags:
Circassia, IPOs, London, AIM
A final flop signals the bitter end to Circassia’s big plans for allergy R&D
Endpoints
Tue, 04/18/17 - 09:34 am
Tags:
Circassia, R&D, allergies, AstraZeneca
$230M deal: AstraZeneca forms COPD drugs collaboration
Bizjournals.com
Sat, 03/18/17 - 09:28 am
Tags:
AstraZeneca, COPD, Circassia, Duaklir, Tudorza
Circassia snags a pair of asthma biotechs for $371M
Fierce Biotech
Fri, 05/15/15 - 09:51 am
Tags:
Circassia, asthma, biotech, Aerocrine, Prosonix
Circassia looks to higher doses to salvage ragweed drug after PhIIb miss
Fierce Biotech
Mon, 12/8/14 - 03:52 pm
Tags:
Circassia, ragweed pollen allergy, Ragweed-SPIRE
Circassia Raises $333.5 Million in IPO for Allergy Shot
Bloomberg
Thu, 03/13/14 - 08:47 am
Tags:
Circassia, allergy shots, IPOs, Cat-SPIRE, cat allergy
Circassia Plans $285 Million IPO to Fund Allergy Vaccines
Bloomberg
Thu, 02/6/14 - 10:18 am
Tags:
Circassia, IPOs, vaccines, allergies
Circassia to Sell Own Cat-Allergy Vaccine If Test Works
Bloomberg
Sat, 03/23/13 - 09:47 am
Tags:
Circassia, vaccines, allergies
Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy, T-Cell Vaccine
Medical News Today
Sat, 02/13/10 - 11:31 am
Tags:
Circassia, Ragweed Allergy, vaccines

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.